Insulet Opens Middle East Regional Headquarters in Riyadh to Expand Diabetes Care Operations

Technology

Insulet Opens Middle East Regional Headquarters in Riyadh to Expand Diabetes Care Operations

Insulet Corporation has announced the opening of its Middle East and North Africa regional headquarters in Riyadh, marking a major strategic expansion of the company’s operations in Saudi Arabia and the wider region.

The new headquarters will serve as Insulet’s primary regional hub for clinical engagement, partner development, market access, and talent investment across the Middle East.

The move reflects the company’s long-term commitment to Saudi Arabia’s healthcare sector as the Kingdom continues to strengthen innovation-driven healthcare services and address rising diabetes rates.

Saudi Arabia is among the countries with the highest prevalence of diabetes globally, making advanced diabetes care technologies a growing priority within the national healthcare system.

Bernard Brisolier described the Riyadh headquarters as one of the company’s most significant regional commitments to date.

He said the establishment of a permanent operational base allows Insulet to move beyond a transactional presence and build long-term partnerships with Saudi Arabia’s healthcare and clinical ecosystem.

According to the company, the regional headquarters will support collaboration on clinical education, patient access programmes, digital health integration, and diabetes care pathways across the region.

To mark the opening, Insulet hosted a high-level launch event in Saudi Arabia on May 8, bringing together healthcare professionals and clinicians to discuss the use of advanced diabetes technologies and early experiences with the company’s Omnipod 5 system.

Dr. Mohammed Al Mehthel said the introduction of Omnipod 5 represents an important advancement for diabetes care in Saudi Arabia and the Middle East, particularly as healthcare systems increasingly adopt technologies aimed at improving patient outcomes.

At the centre of Insulet’s regional strategy is the Omnipod 5 Automated Insulin Delivery System, the company’s tubeless wearable insulin pump designed for people living with type 1 diabetes.

The automated insulin delivery system adjusts insulin levels every five minutes and is designed to improve glucose management while reducing the need for multiple daily injections.

The system is compatible with the Abbott FreeStyle Libre 2 Plus sensor and Dexcom G7 sensor in Saudi Arabia, Kuwait, and the UAE, while Qatar currently supports compatibility with the Dexcom G7 sensor.

Insulet said the expansion reinforces its broader commitment to improving access to next-generation diabetes care solutions across the Middle East.